Abstract
Dynamic contrast-enhanced ultrasonography (DCEUS) using the contrast agent Sonovue and vascular recognition imaging software is a novel technique that enables the detection of microvessels and quantitative assessment of solid tumor perfusion using raw linear data. Clinical trials have shown that DCE-US can be used to assess the anticancer efficacy of antiangiogenic treatment, for which conventional efficacy criteria based on size are unsuitable. Reduction in tumor vascularization can easily be detected in responders after 1–2 weeks and is correlated with progression-free survival and overall survival. DCE-US is supported by the French Cancer National Institut. This program is currently studying the technique in metastatic breast cancer, melanoma, colon cancer, gastrointestinal stromal tumor, and renal cell carcinoma, as well as in primary hepatocellular carcinoma, to establish the optimal perfusion parameters and timing for quantitative anticancer efficacy assessments.
Similar content being viewed by others
References
Rehman S, Jayson GC (2005) Molecular imaging of antiangiogenic agents. Oncologist 10:92–103
Schwartz L (2004) Conventional and novel techniques for therapeutic response assessment. Radiological Society North America (RSNA). 90th Scientific Assembly and Annual Meeting, Chicago, December 2004
Benjamin RS, Choi H, Macapinlac HA et al (2007) We should desist using Recist, at least in GIST. J Clin Oncol 25:1760–1764
Cosgrove D (2003) Angiogenesis imaging-ultrasound. Br J Radiol 76(Spec No 1):S43–S49
Lassau N, Koscielny S, Opolon P et al (2001) Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol 36:50–55
Escudier B, Lassau N, Couanet D et al (2002) Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13:1029–1035
Greis C (2004) Technology overview: SonoVue (Bracco, Milan). Eur Radiol 14[Suppl 8]:P11–P15
Lassau N, Lamuraglia M, Vanel D et al (2005) Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 16:1054–1060
Lassau N, Lamuraglia M, Chami L et al (2006) Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 187:1267–1273
Lamuraglia M, Escudier B, Chami L et al (2006) To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 42:2472–2479
Escudier B, Lassau N, Angevin E et al (2007) Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13:1801–1809
Blay JY, Landi B, Bonvalot S et al (2005) Recommendations for the management of GIST patients. Bull Cancer 92:907–918
Choi H, Faria S, Benjamin R et al (2002) Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIST) with CT and PET: a quantitative analysis (abstract 583). RSNA Scientific program 2002, Chicago, IL
De Giorgi U, Aliberti C, Benea G, et al (2005) Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 11:6171–6176
Le Cesne A, Landi B, Bonvalot S et al (2005) Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales. Hepato-Gastro 12:377–389
Lamuraglia M, Le Cesne A, Chami L et al (2006) Dynamic contrast-enhanced Doppler ultrasound (DCEUS) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM). J Clin Oncol (2006 ASCO Annual Meeting Proceedings, Post Meeting Edition, June 20) 24:529S
Le Cesne A, Landi B, Bonvalot S et al (2006) Recommendations for the management of gastro-intestinal stromal tumors. Ann Pathol 26:231–234
Kaelin WG (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673–682
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
McCarville MB, Streck CJ, Dickson PV et al (2006) Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. Radiology 240:73–81
Kruskal JB (2006) Science to practice: will improved assessment of response to antiangiogenic therapies be achieved with contrast-enhanced grayscale US? Radiology 240:1–2
Soria JC, Lazar V, Lassau N et al (2007) Sorafenib (S) and dacarbazine (D) combination in patients with advanced malignant solid tumors: phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US). 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 25[Suppl 18]:151s
Lassau N, Chami L, Peronneau P (2007) Imaging of melanoma: accuracy of ultrasonography before and after contrast injection for diagnostic and early evaluation of treatment. Bull Cancer 94:93–98
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lassau, N., Chami, L., Benatsou, B. et al. Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol Suppl 17 (Suppl 6), 89–98 (2007). https://doi.org/10.1007/s10406-007-0233-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10406-007-0233-6